{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:38:47Z","timestamp":1792643927253,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>Acromegaly is a complex endocrine disease with multiple comorbidities. Treatment to obtain biochemical remission includes surgery, medical therapy and radiation. We aimed to describe comorbidities, treatment patterns and cost-of-illness in patients with acromegaly in Sweden.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Design<\/jats:title>\n<jats:p>A nationwide population-based study.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients with acromegaly were identified and followed in national registers in Sweden. Longitudinal treatment patterns were assessed in patients diagnosed between July 2005 and December 2013. The cost-of-illness during 2013 was estimated from a societal perspective among patients diagnosed between 1987 and 2013.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among 358 patients with acromegaly (48% men, mean age at diagnosis 50.0 (<jats:sc>s.d.<\/jats:sc> 15.3) years) at least one comorbidity was reported in 81% (<jats:italic>n<\/jats:italic>\u2009=\u2009290). The most common comorbidities were hypertension (40%, <jats:italic>n<\/jats:italic>\u2009=\u2009142), neoplasms outside the pituitary (30%, <jats:italic>n<\/jats:italic>\u2009=\u2009109), hypopituitarism (22%, <jats:italic>n<\/jats:italic>\u2009=\u200980) and diabetes mellitus (17%, <jats:italic>n<\/jats:italic>\u2009=\u200961). Acromegaly treatment was initiated on average 3.7 (<jats:sc>s.d.<\/jats:sc> 6.9) months after diagnosis. Among the 301 treated patients, the most common first-line treatments were surgery (60%, <jats:italic>n<\/jats:italic>\u2009=\u2009180), somatostatin analogues (21%, <jats:italic>n<\/jats:italic>\u2009=\u200964) and dopamine agonists (14%, <jats:italic>n<\/jats:italic>\u2009=\u200941). After primary surgery, 24% (<jats:italic>n<\/jats:italic>\u2009=\u200944) received somatostatin analogues. The annual per-patient cost was \u20ac12\u2009000; this was \u20ac8700 and \u20ac16\u2009000 if diagnosed before or after July 2005, respectively. The cost-of-illness for acromegaly and its comorbidities was 77% from direct costs and 23% from production loss.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The prevalence of comorbidity is high in patients with acromegaly. The most common first-line treatment in acromegalic patients was surgery followed by somatostatin analogues. The annual per-patient cost of acromegaly and its comorbidities was \u20ac12\u2009000.<\/jats:p>\n<\/jats:sec>","DOI":"10.1530\/eje-16-0623","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T13:16:27Z","timestamp":1479302187000},"page":"203-212","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":44,"title":["Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study"],"prefix":"10.1093","volume":"176","author":[{"given":"Eva","family":"Les\u00e9n","sequence":"first","affiliation":[{"name":"1Nordic Health EconomicsGothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Granfeldt","sequence":"additional","affiliation":[{"name":"1Nordic Health EconomicsGothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Houchard","sequence":"additional","affiliation":[{"name":"2IpsenBoulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Dinet","sequence":"additional","affiliation":[{"name":"2IpsenBoulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Berthon","sequence":"additional","affiliation":[{"name":"2IpsenBoulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S","family":"Olsson","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine and Clinical NutritionInstitute of Medicine, Sahlgrenska Academy, University of Gothenburg and Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingela","family":"Bj\u00f6rholt","sequence":"additional","affiliation":[{"name":"1Nordic Health EconomicsGothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudmundur","family":"Johannsson","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine and Clinical NutritionInstitute of Medicine, Sahlgrenska Academy, University of Gothenburg and Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2016120818251377000_176.2.203.1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009965803750"},{"key":"2016120818251377000_176.2.203.2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11102-015-0655-4","article-title":"The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013","volume":"18","author":"Hoskuldsdottir","year":"2015","journal-title":"Pituitary"},{"key":"2016120818251377000_176.2.203.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra062453"},{"key":"2016120818251377000_176.2.203.4","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0022"},{"key":"2016120818251377000_176.2.203.5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1191"},{"key":"2016120818251377000_176.2.203.6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0267"},{"key":"2016120818251377000_176.2.203.7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.0954-6820.1988.tb15881.x","article-title":"Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984","volume":"223","author":"Bengtsson","year":"1988","journal-title":"Acta Medica Scandinavica"},{"key":"2016120818251377000_176.2.203.8","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0033"},{"key":"2016120818251377000_176.2.203.9","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0310-7"},{"key":"2016120818251377000_176.2.203.10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2297"},{"key":"2016120818251377000_176.2.203.11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000375451","article-title":"Quality of life in acromegaly","volume":"103","author":"Webb","year":"2015","journal-title":"Neuroendocrinology"},{"key":"2016120818251377000_176.2.203.12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.17925\/USE.2014.10.01.79","article-title":"Improving quality of life in patients with pituitary tumours","volume":"10","author":"Crespo","year":"2014","journal-title":"US Endocrinology"},{"key":"2016120818251377000_176.2.203.13","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0702-1"},{"key":"2016120818251377000_176.2.203.14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2149"},{"key":"2016120818251377000_176.2.203.15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.1.168"},{"key":"2016120818251377000_176.2.203.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.21"},{"key":"2016120818251377000_176.2.203.17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700"},{"key":"2016120818251377000_176.2.203.18","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ghir.2005.06.008","article-title":"Neurosurgical approach to treating pituitary adenomas","volume":"15","author":"Laws","year":"2005","journal-title":"Growth Hormone and IGF Research"},{"key":"2016120818251377000_176.2.203.19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4158\/EP14574.OR","article-title":"Radiotherapy versus radiosurgery in treating patients with acromegaly: a systematic review and meta-analysis","volume":"21","author":"Abu Dabrh","year":"2015","journal-title":"Endocrine Practices"},{"key":"2016120818251377000_176.2.203.20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2002.00990.x"},{"key":"2016120818251377000_176.2.203.21","unstructured":"Statistics Sweden . Statistikdatabasen: Genomsnittlig grund- och m\u00e5nadsl\u00f6n samt kvinnors l\u00f6n i procent av m\u00e4ns l\u00f6n efter sektor, yrke (SSYK 2012), k\u00f6n och \u00e5lder. \u00c5r 2014. (Statistical database in Swedish). Accessed on 1 Sep 2015."},{"key":"2016120818251377000_176.2.203.22","unstructured":"Statistics Sweden. Mer om Arbetskostnadsindex (AKI) (Swedish). (Available at http:\/\/www.scb.se\/sv_\/Hitta-statistik\/Statistik-efter-amne\/Arbetsmarknad\/Loner-och-arbetskostnader\/Arbetskostnadsindex-for-arbetare-och-tjansteman-inom-privat-sektor-AKI\/7965\/Mer-om-Arbetskostnadsindex-AKI\/). Accessed on 1 Sep 2015."},{"key":"2016120818251377000_176.2.203.23","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0356"},{"key":"2016120818251377000_176.2.203.24","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0697"},{"key":"2016120818251377000_176.2.203.25","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0358"},{"key":"2016120818251377000_176.2.203.26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/EJE-12-0602","article-title":"Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register","volume":"168","author":"Sch\u00f6fl","year":"2013","journal-title":"European Journal of Endocrinology"},{"key":"2016120818251377000_176.2.203.27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11102-012-0384-x","article-title":"Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA)","volume":"16","author":"Sesmilo","year":"2013","journal-title":"Pituitary"},{"key":"2016120818251377000_176.2.203.28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/cen.12112","article-title":"Emerging trends in the diagnosis and treatment of acromegaly in Canada","volume":"79","author":"Vallette","year":"2013","journal-title":"Clinical Endocrinology"},{"key":"2016120818251377000_176.2.203.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.03982.x"},{"key":"2016120818251377000_176.2.203.30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/11599680-000000000-00000","article-title":"Cost of clinical management of acromegaly in Spain","volume":"32","author":"Roset","year":"2012","journal-title":"Clinical Drug Investigation"},{"key":"2016120818251377000_176.2.203.31","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/BF03345306","article-title":"Cost-of-illness study in acromegalic patients in Italy","volume":"27","author":"Didoni","year":"2004","journal-title":"Journal of Endocrinological Investigation"},{"key":"2016120818251377000_176.2.203.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02786.x"},{"key":"2016120818251377000_176.2.203.33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10198-010-0261-3","article-title":"Atrial fibrillation: the cost of illness in Sweden","volume":"12","author":"Ericson","year":"2011","journal-title":"European Journal of Health Economics"},{"key":"2016120818251377000_176.2.203.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.06.029"},{"key":"2016120818251377000_176.2.203.35","unstructured":"Lundqvist A Andersson E Steen Carlsson K. Kostnader f\u00f6r cancer i Sverige idag och \u00e5r 2040 (Costs of cancer in Sweden today and year 2040; Report in Swedish). ISSN: 1651-7598, 2016."},{"key":"2016120818251377000_176.2.203.36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/jc.2014-3525","article-title":"Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in sweden","volume":"100","author":"Olsson","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2016120818251377000_176.2.203.37","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1210\/jc.2015-1475","article-title":"Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a Swedish nationwide study","volume":"100","author":"Olsson","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/176\/2\/203.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/176\/2\/203.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:34:37Z","timestamp":1676392477000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/176\/2\/203\/6655042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":37,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/eje-16-0623","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}